Complications of hypertension and the role of angiotensin receptor blockers in hypertension trials

References

• Flaa A, Kjeldsen SE. Are all the hypertensives made equal? Herz31, 323–330 (2006).
   PubMed Web of Science ®Google Scholar
• Timmermans PB, Wong PC, Chiu AT et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev.45, 205–251 (1993).
   PubMed Web of Science ®Google Scholar
• Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J. Hum. Hypertens.14(Suppl. 1), S73–S86 (2000).
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med.322, 1561–1566 (1990).
   PubMed Web of Science ®Google Scholar
• Weber KT. Fibrosis and hypertensive heart disease. Curr. Opin. Cardiol.15, 264–272 (2000).
   PubMed Web of Science ®Google Scholar
• Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press.12, 70–88 (2003).
   PubMed Web of Science ®Google Scholar
• Booz GW, Baker KM. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc. Res.30, 537–543 (1995).
   PubMed Web of Science ®Google Scholar
• Gonzalez A, Lopez B, Querejeta R, Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J. Mol. Cell Cardiol.34, 1585–1593 (2002).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens.5, 95–110 (1992).
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Schlaich MP, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol. Dial. Transplant.13, 564–569 (1998).
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med.115, 41–46 (2003).
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) Study. Circulation108, 684–690 (2003).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Strand AH, Julius S, Okin PM. Mechanism of angiotensin II type 1 receptor blocker action in the regression of left ventricular hypertrophy. J. Clin. Hypertens.8, 487–492 (2006).
   PubMedGoogle Scholar
• Martina B, Dieterle T, Weinbacher M, Battegay E. Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. Cardiology92, 110–114 (1999).
   PubMed Web of Science ®Google Scholar
• Gaudio C, Ferri FM, Giovannini M et al. Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. J. Cardiovasc. Pharmacol.42, 622–628 (2003).
   PubMed Web of Science ®Google Scholar
• Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A. Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J. Am. Coll. Cardiol.43, 2116–2123 (2004).
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J. Hypertens.20, 2293–2300 (2002).
   PubMed Web of Science ®Google Scholar
• De Rosa ML, Cardace P, Rossi M, Baiano A, de Cristofaro A. Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J. Hum. Hypertens.16, 133–140 (2002).
   PubMed Web of Science ®Google Scholar
• Avanza AC Jr, El Aouar LM, Mill JG. Reduction in left ventricular hypertrophy in hypertensive patients treated with enalapril, losartan or the combination of enalapril and losartan. Arq. Bras. Cardiol.74, 103–117 (2000).
   PubMedGoogle Scholar
• Raasch W, Johren O, Schwartz S, Gieselberg A, Dominiak P. Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR. J. Hypertens.22, 611–618 (2004).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Kanno Y, Kaneko K et al. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther. Apher. Dial.8, 320–327 (2004).
   PubMed Web of Science ®Google Scholar
• Bennett MR, Macdonald K, Chan SW, Boyle JJ, Weissberg PL. Cooperative interactions between RB and p53 regulate cell proliferation, cell senescence, and apoptosis in human vascular smooth muscle cells from atherosclerotic plaques. Circ. Res.82, 704–712 (1998).
   PubMed Web of Science ®Google Scholar
• Diep QN, Li JS, Schiffrin EL. In vivo study of AT(1) and AT(2) angiotensin receptors in apoptosis in rat blood vessels. Hypertension34, 617–624 (1999).
   PubMed Web of Science ®Google Scholar
• Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin–angiotensin system. Circulation109, 8–13 (2004).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens.21, 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin II receptor blockers increase the risk of myocardial infarction? Eur. Heart J.26, 2381–2386 (2005).
   PubMed Web of Science ®Google Scholar
• Anavekar NS, Solomon SD. Angiotensin II receptor blockade and ventricular remodelling. J. Renin Angiotensin Aldosterone Syst.6, 43–48 (2005).
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet363, 2049–2051 (2004).
   PubMed Web of Science ®Google Scholar
• Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J. Am. Coll. Cardiol.45, 1832–1839 (2005).
   PubMed Web of Science ®Google Scholar
• Aksnes TA, Flaa A, Strand A, Kjeldsen SE. Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. J. Hypertens.25, 15–23 (2007).
   PubMed Web of Science ®Google Scholar
• Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation101, 2612–2617 (2000).
   PubMed Web of Science ®Google Scholar
• Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J. Am. Coll. Cardiol.41, 2197–2204 (2003).
   PubMed Web of Science ®Google Scholar
• Lopez B, Querejeta R, Varo N et al. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation104, 286–291 (2001).
   PubMed Web of Science ®Google Scholar
• Klein HU, Goette A. Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? J. Am. Coll. Cardiol.41, 2205–2206 (2003).
   PubMed Web of Science ®Google Scholar
• Schmieder R, Kjeldsen S, Julius S, McInnes GT, Zanchetti A, Hua T. Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade: the VALUE-trial. J. Hypertens.24(Suppl. 4), S3 (2006).
   PubMed Web of Science ®Google Scholar
• Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End point reduction in hypertension (LIFE) study. J. Am. Coll. Cardiol.45, 712–719 (2005).
   PubMed Web of Science ®Google Scholar
• Mackay JMG. The Atlas of Heart Disease and Stroke. WHO (2004).
   Google Scholar
• MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet335, 765–774 (1990).
   PubMed Web of Science ®Google Scholar
• Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360, 1903–1913 (2002).
   PubMed Web of Science ®Google Scholar
• Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet335, 827–838 (1990).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Julius S, Hedner T, Hansson L. Stroke is more common than myocardial infarction in hypertension: analysis based on 11 major randomized intervention trials. Blood Press.10, 190–192 (2001).
   PubMed Web of Science ®Google Scholar
• Brown MJ, Brown J. Does angiotensin-II protect against strokes? Lancet2, 427–429 (1986).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahlof B, Devereux RB et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA288, 1491–1498 (2002).
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on COgnition and Prognosis in the Elderly (SCOPE). J. Am. Coll. Cardiol.44, 1175–1180 (2004).
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality after Stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke36, 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs65(Suppl. 2), 29–39 (2005).
   PubMed Web of Science ®Google Scholar
• Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension44, 595–601 (2004).
   PubMed Web of Science ®Google Scholar
• Montalescot G, Collet JP. Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. Eur. Heart J.26, 2616–2622 (2005).
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases: renoprotective benefits of renin–angiotensin system inhibition. Ann. Intern. Med.136, 604–615 (2002).
   PubMed Web of Science ®Google Scholar
• Navar LG, Harrison-Bernard LM, Imig JD, Mitchell KD. Renal actions of angiotensin II and AT1 receptor blockers. In: Angiotensin II Receptor Antagonists. Epstein M, Brunner HR (Eds). Hanley & Belfus Inc., PA, USA 189–214 (2001).
   Google Scholar
• Ruiz-Ortega M, Esteban V, Ruperez M et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr. Opin. Nephrol. Hypertens.15, 159–166 (2006).
   PubMed Web of Science ®Google Scholar
• Laverman GD, Remuzzi G, Ruggenenti P. ACE inhibition versus angiotensin receptor blockade: which is better for renal and cardiovascular protection? J. Am. Soc. Nephrol.15(Suppl. 1), S64–S70 (2004).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359, 1004–1010 (2002).
   PubMed Web of Science ®Google Scholar
• Ibsen H, Wachtell K, Olsen MH et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J. Hypertens.22, 1805–1811 (2004).
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med.345, 851–860 (2001).
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med.345, 861–869 (2001).
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J. Am. Soc. Nephrol.16, 3038–3045 (2005).
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet361, 117–124 (2003).
   PubMed Web of Science ®Google Scholar
• Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J.321, 1440–1444 (2000).
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet366, 2026–2033 (2005).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care14, 173–194 (1991).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth. J. Med.50, 191–197 (1997).
   PubMed Web of Science ®Google Scholar
• Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of Type 2 diabetes mellitus. J. Clin. Invest.104, 787–794 (1999).
   PubMed Web of Science ®Google Scholar
• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes37, 1595–1607 (1988).
   PubMed Web of Science ®Google Scholar
• Sowers JR. Insulin resistance and hypertension. Am. J. Physiol. Heart Circ. Physiol.286, H1597–H1602 (2004).
   PubMed Web of Science ®Google Scholar
• Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet. Med.20, 255–268 (2003).
   PubMed Web of Science ®Google Scholar
• Benson SC, Pershadsingh HA, Ho CI et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension43, 993–1002 (2004).
   PubMed Web of Science ®Google Scholar
• Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: a systematic review. Diabetes Care27, 247–255 (2004).
   PubMed Web of Science ®Google Scholar
• Aksnes TA, Reims HM, Kjeldsen SE, Mancia G. Antihypertensive treatment and new-onset diabetes mellitus. Curr. Hypertens. Rep.7, 298–303 (2005).
   PubMed Web of Science ®Google Scholar
• Henriksen EJ, Jacob S. Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J. Cell Physiol.196, 171–179 (2003).
   PubMed Web of Science ®Google Scholar
• Jacob S, Henriksen EJ, Fogt DL, Dietze GJ. Effects of trandolapril and verapamil on glucose transport in insulin-resistant rat skeletal muscle. Metabolism45, 535–541 (1996).
   PubMed Web of Science ®Google Scholar
• Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension40, 609–611 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Seghieri G, Muscelli E. Insulin and the renin–angiotensin–aldosterone system: influence of ACE inhibition. J. Cardiovasc. Pharmacol.24(Suppl. 3), S61–S69 (1994).
   Google Scholar
• Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME. Improved islet morphology after blockade of the renin–angiotensin system in the ZDF rat. Diabetes53, 989–997 (2004).
   PubMed Web of Science ®Google Scholar
• Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia41, 127–133 (1998).
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J. Hypertens.20, 1879–1886 (2002).
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med.15, 539–553 (1998).
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Julius S, Mancia G et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. J. Hypertens.24, 1405–1412 (2006).
   PubMed Web of Science ®Google Scholar
• Teo K, Yusuf S, Sleight P et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am. Heart J.148, 52–61 (2004).
   PubMed Web of Science ®Google Scholar
• Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation114, 838–854 (2006).
   PubMed Web of Science ®Google Scholar
• Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation114, 855–860 (2006).
   PubMed Web of Science ®Google Scholar
• Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med.354, 1685–1697 (2006).
   PubMed Web of Science ®Google Scholar